Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Saturday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

Shares of Oragenics stock opened at $0.52 on Friday. The company has a market capitalization of $2.33 million, a P/E ratio of -0.06 and a beta of 0.50. Oragenics has a 1 year low of $0.47 and a 1 year high of $7.74. The company’s fifty day moving average is $1.09 and its two-hundred day moving average is $1.41.

Oragenics (NYSE:OGEN) last announced its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Hedge Funds Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC bought a new stake in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent SEC filing. 18.71% of the stock is owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.